These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33457084)

  • 1. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
    Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
    Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
    Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
    J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
    Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
    Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
    Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential Expression of CKLF-like MARVEL Transmembrane Domain-Containing Protein 6 and Programmed Cell Death Ligand 1 as Prognostic Biomarkers in Upper Tract Urothelial Carcinoma.
    Kdimati S; Christoph C; Glass Ä; Engel N; Dräger DL; Maletzki C; Becker AS; Zimpfer A
    Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CMTM6, a potential immunotherapy target.
    Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
    Zhao Y; Zhang M; Pu H; Guo S; Zhang S; Wang Y
    Front Oncol; 2020; 10():585961. PubMed ID: 33552963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
    Zhang C; Zhao S; Wang X
    Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
    Koh YW; Han JH; Haam S; Jung J; Lee HW
    Oncoimmunology; 2019; 8(10):e1629261. PubMed ID: 31646074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients.
    Li X; Chen L; Gu C; Sun Q; Li J
    PeerJ; 2020; 8():e9536. PubMed ID: 32874775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
    Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
    Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
    Wu X; Lan X; Hu W; Zhang W; Lai X; Xu S; Li J; Qiu W; Wang W; Xiao J; Wang F; Ding Y; Liang L
    Cancer Immunol Immunother; 2021 Nov; 70(11):3235-3248. PubMed ID: 33818637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
    Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
    Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
    Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
    Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
    J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
    Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
    Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
    Tang T; Huang X; Zhang G; Lu M; Hong Z; Wang M; Huang J; Zhi X; Liang T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
    Zhang T; Yu H; Dai X; Zhang X
    Front Immunol; 2022; 13():971428. PubMed ID: 35958549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
    Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
    Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.